Literature DB >> 15013815

Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases.

M Jane Cox Rosemond1, Lisa St John-Williams, Toshiro Yamaguchi, Toshio Fujishita, John S Walsh.   

Abstract

S-1360, a 1,3-diketone derivative, was the first HIV integrase inhibitor to enter human trials. Clinical data suggested involvement of non-cytochrome P450 clearance pathways, including reduction and glucuronidation. Reduction of S-1360 generates a key metabolite in humans, designated HP1, and constitutes a major clearance pathway. For characterization of subcellular location and cofactor dependence of HP1 formation, [(14)C]-S-1360 was incubated with commercially available pooled human liver fractions, including microsomes, cytosol, and mitochondria, followed by HPLC analysis with radiochemical detection. Incubations were performed in the presence and absence of the cofactors NADH or NADPH. Results showed that the enzyme system responsible for generation of HP1 in vitro is cytosolic and NADPH-dependent, implicating aldo-keto reductases (AKRs) and/or short-chain dehydrogenases/reductases (SDRs). A validated LC/MS/MS method was developed for investigating the reduction of S-1360 in detail. The reduction reaction exhibited sigmoidal kinetics with a K(m,app) of 2 microM and a Hill coefficient of 2. The ratio of V(max)/K(m) was approximately 1 ml/(min mg cytosolic protein). The S-1360 kinetic data were consistent with positive cooperativity and a single enzyme system. The relative contributions of AKRs and SDRs were examined through the use of chemical inhibitors. For these experiments, non-radiolabeled S-1360 was incubated with pooled human liver cytosol and NADPH in the presence of inhibitors, followed by quantitation of HP1 by LC/MS/MS. Quercetin and menadione produced approximately 30% inhibition at a concentration of 100 microM. Enzymes sensitive to these inhibitors include the carbonyl reductases (CRs), a subset of the SDR enzyme family predominantly located in the cytosol. Flufenamic acid and phenolphthalein were the most potent inhibitors, with > 67% inhibition at a concentration of 20 microM, implicating the AKR enzyme family. The cofactor dependence, subcellular location, and chemical inhibitor results implicated the aldo-keto reductase family of enzymes as the most likely pathway for generation of the major metabolite HP1 from S-1360.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15013815     DOI: 10.1016/j.cbi.2003.12.001

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  26 in total

Review 1.  Role of Marine Natural Products in the Genesis of Antiviral Agents.

Authors:  Vedanjali Gogineni; Raymond F Schinazi; Mark T Hamann
Journal:  Chem Rev       Date:  2015-08-28       Impact factor: 60.622

2.  Synthesis of novel 4-Boc-piperidone chalcones and evaluation of their cytotoxic activity against highly-metastatic cancer cells.

Authors:  Carlimar Ocasio-Malavé; Metsiel J Donate; María M Sánchez; Jesús M Sosa-Rivera; Joseph W Mooney; Tomás A Pereles-De León; Néstor M Carballeira; Beatriz Zayas; Christian E Vélez-Gerena; Magaly Martínez-Ferrer; David J Sanabria-Ríos
Journal:  Bioorg Med Chem Lett       Date:  2019-10-28       Impact factor: 2.823

Review 3.  The aldo-keto reductase superfamily and its role in drug metabolism and detoxification.

Authors:  Oleg A Barski; Srinivas M Tipparaju; Aruni Bhatnagar
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

4.  Design and synthesis of novel iminothiazinylbutadienols and divinylpyrimidinethiones as ARE inducers.

Authors:  Lin Chen; Sadagopan Magesh; Hong Wang; Chung S Yang; Ah-Ng Tony Kong; Longqin Hu
Journal:  Bioorg Med Chem Lett       Date:  2013-12-24       Impact factor: 2.823

5.  Metabolism of bupropion by carbonyl reductases in liver and intestine.

Authors:  Jamie N Connarn; Xinyuan Zhang; Andrew Babiskin; Duxin Sun
Journal:  Drug Metab Dispos       Date:  2015-04-22       Impact factor: 3.922

6.  Biochemical activity of RAGs is impeded by Dolutegravir, an HIV integrase inhibitor.

Authors:  Namrata M Nilavar; Amita M Paranjape; Sathees C Raghavan
Journal:  Cell Death Discov       Date:  2020-06-12

7.  A novel synthetic mono-carbonyl analogue of curcumin, A13, exhibits anti-inflammatory effects in vivo by inhibition of inflammatory mediators.

Authors:  Yi Wang; Congcong Yu; Yong Pan; Xuyi Yang; Yi Huang; Zhiguo Feng; Xiaokun Li; Shulin Yang; Guang Liang
Journal:  Inflammation       Date:  2012-04       Impact factor: 4.092

8.  Inhibition of high glucose-induced inflammatory response and macrophage infiltration by a novel curcumin derivative prevents renal injury in diabetic rats.

Authors:  Yong Pan; Yi Wang; Lu Cai; Yuepiao Cai; Jie Hu; Congcong Yu; Jianling Li; Zhiguo Feng; Shulin Yang; Xiaokun Li; Guang Liang
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

9.  Characterization of a replication-competent, integrase-defective human immunodeficiency virus (HIV)/simian virus 40 chimera as a powerful tool for the discovery and validation of HIV integrase inhibitors.

Authors:  Dirk Daelemans; Richard Lu; Erik De Clercq; Alan Engelman
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

Review 10.  Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors.

Authors:  Erik Serrao; Srinivas Odde; Kavya Ramkumar; Nouri Neamati
Journal:  Retrovirology       Date:  2009-03-05       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.